Evaluation of the possibility of using the Androscan-MIT device for diagnosis and minimally invasive assessment of conservative therapy outcomes in patients with vasculogenic erectile dysfunction

Aliev R.R., Neymark A.I., Davydov A.V.

Department of Urology and Andrology with a Course of Continuing Professional Education, Altai State Medical University, Ministry of Health of the Russian Federation, Barnaul, Russia

Introduction. Erectile dysfunction (ED) remains one of the important issues in modern urology, as it affects not only the quality of life but also the psychological and reproductive health of patients. Diagnostic challenges persist, as there is still no universal, minimally invasive method to evaluate the quality of erection and the efficiency of therapy in patients with a confirmed diagnosis of ED.
Aim. To assess the feasibility of using the Androscan-MIT device as a minimally invasive tool for monitoring the efficiency of conservative treatment in patients with vasculogenic erectile dysfunction.
Materials and Methods. The study included 80 men aged 37 to 61 years with mild to moderate ED and 20 healthy volunteers as a control group. Patients were divided into four groups: group 1 (n=30): patients received local negative pressure therapy (LOD-therapy), low-intensity shockwave therapy (LiSWT), and Avantron chair stimulation (10 sessions); group 2 (n=30): patients received daily phosphodiesterase type 5 inhibitor (PDE5i) therapy at a dose of 5 mg for 2 months; group 3 (n=20): patients received combined therapy including LOD-therapy, LiSWT, Avantron chair stimulation, and platelet-rich plasma (PRP) injections (5 sessions); group 4 (n=20): control group of healthy volunteers.
Therapeutic efficacy was assessed using the IIEF-5 questionnaire (International Index of Erectile Function) and Androscan-MIT measurements before and after treatment.
Results. In Group 3, a significant improvement was observed after therapy: the IIEF-5 score increased to 21.1±2.1, corresponding to a 39.7% rise from baseline.
Repeat nocturnal penile tumescence (NPT) monitoring demonstrated erectile function parameters comparable to those in the control group. The absolute increase in penile diameter reached 12.5±0.4 mm (+48.8% from baseline).
The average number of effective nocturnal erections increased to 4.6±0.4 (+67.6%), and the average duration of each effective erection reached 20.9±1.5 minutes (+36.6%). The total erection time per night was 81.8±5.3 minutes (+74.8% from baseline). In Groups 1 and 2, no statistically significant changes in these parameters were recorded compared to baseline.
Conclusion. The use of the Androscan-MIT device allowed for effective diagnosis of vasculogenic erectile dysfunction and minimally invasive assessment of therapeutic outcomes. The observed improvements following treatment confirm the potential of Androscan-MIT for both diagnostic evaluation and monitoring of conservative therapy efficiency in patients with vasculogenic ED.

Keywords

About the Authors

Corresponding author: R.R. Aliev – Ph.D. Student, Department of Urology and Andrology with a Course of Continuing Professional Education, Altai State Medical University, Ministry of Health of the Russian Federation, Barnaul, Russia; e-mail: ruslanaliev@bk.ru

Similar Articles